{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:31Z","timestamp":1794047491390,"version":"4.8.0"},"reference-count":34,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Children with hemophilia have a significantly higher risk of intracranial hemorrhage (ICH) compared to the normal population. Prophylaxis reduces the risk of ICH and earlier initiation of prophylaxis may now be feasible, especially in hemophilia A (HA). The aim of the study is to explore the potential for preventing ICH by earlier start of prophylaxis by assessing the natural course of ICH before the initiation of prophylaxis and describe timing and incidence (clinicaltrials gov. Identifier: NCT02979119). In total, 2,727 children (2,275 with HA; 452 with hemophilia B [HB]) were included from the PedNet Registry, followed from 28 days until 36 months of life. ICH was observed in 61 children (incidence 2.2%; 10 per 1,000 patient years), with 75% of cases occurring before 1 year of age. Cumulative incidence was significantly lower in HB (0.9%) compared to HA (2.5%) and in non-severe HA (0.7%) compared to severe HA (3.5%). ICH occurred early, with a rise at 3 months, and a median age of 7.0 months in severe HA and 5.4 months in severe HB. In 40% of children, ICH occurred before the diagnosis of hemophilia was established, underscoring the importance of early diagnosis. Assuming that prophylaxis would have been started at the time of diagnosis and preventing all ICH in children with severe HA, the number needed to treat with prophylaxis would be 44 patients to prevent one ICH. Hopefully, prophylaxis options allowing initiation early in life, ideally before 3 months of age for children with severe HA, will reduce the incidence of ICH in the future.<\/jats:p>","DOI":"10.3324\/haematol.2024.285874","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T14:45:04Z","timestamp":1732805104000},"page":"914-922","source":"Crossref","is-referenced-by-count":7,"title":["Intracranial hemorrhage before start of prophylaxis in children with hemophilia: incidence, timing, and potential for prevention"],"prefix":"10.3324","volume":"110","author":[{"given":"Nadine G.","family":"Andersson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marloes","family":"De Kovel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseline","family":"D\u2019Oiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Konigs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Male","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigridur","family":"Sigurgisladottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Zapotocka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathelijn","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"74176","doi-asserted-by":"crossref","unstructured":"Ljung RC. Intracranial haemorrhage in haemophilia A and B. Br J Haematol. 2008; 140(4):378-384.","DOI":"10.1111\/j.1365-2141.2007.06949.x"},{"key":"74177","doi-asserted-by":"crossref","unstructured":"de Tezanos Pinto M, Fernandez J, Perez Bianco PR. Update of 156 episodes of central nervous system bleeding in hemophiliacs. Haemostasis. 1992; 22(5):259-267.","DOI":"10.1159\/000216333"},{"key":"74178","doi-asserted-by":"crossref","unstructured":"Morales G, Matute E, Murray J, Hardy DJ, O\u2019Callaghan ET, Tlacuilo-Parra A. Is executive function intact after pediatric intracranial hemorrhage? A sample of Mexican children with hemophilia. Clin Pediatr (Phila). 2013; 52(10):950-959.","DOI":"10.1177\/0009922813495311"},{"key":"74179","doi-asserted-by":"crossref","unstructured":"Andersson NG, Wu R, Carcao M. Long-term follow-up of neonatal intracranial haemorrhage in children with severe haemophilia. Br J Haematol. 2020; 190(2):e101-e104.","DOI":"10.1111\/bjh.16740"},{"key":"74180","doi-asserted-by":"crossref","unstructured":"Stieltjes N, Calvez T, Demiguel V. Intracranial haemorrhages in French haemophilia patients (1991-2001): clinical presentation, management and prognosis factors for death. Haemophilia. 2005; 11(5):452-458.","DOI":"10.1111\/j.1365-2516.2005.01090.x"},{"key":"74181","doi-asserted-by":"crossref","unstructured":"Witmer CM. Low mortality from intracranial haemorrhage in paediatric patients with haemophilia. Haemophilia. 2015; 21(5):e359-363.","DOI":"10.1111\/hae.12716"},{"key":"74182","doi-asserted-by":"crossref","unstructured":"Zanon E, Pasca S, Demartis F. Intracranial haemorrhage in haemophilia patients is still an open issue: the final results of the Italian EMO.REC Registry. J Clin Med. 2022; 11(7):1969.","DOI":"10.3390\/jcm11071969"},{"key":"74183","doi-asserted-by":"crossref","unstructured":"Zwagemaker AF, Gouw SC, Jansen JS. Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis. Blood. 2021; 138(26):2853-2873.","DOI":"10.1182\/blood.2021011849"},{"key":"74184","doi-asserted-by":"crossref","unstructured":"Davies J, Kadir RA. Mode of delivery and cranial bleeding in newborns with haemophilia: a systematic review and meta-analysis of the literature. Haemophilia. 2016; 22(1):32-38.","DOI":"10.1111\/hae.12726"},{"key":"74185","doi-asserted-by":"crossref","unstructured":"Chalmers EA, Alamelu J, Collins PW. Intracranial haemorrhage in children with inherited bleeding disorders in the UK 2003-2015: a national cohort study. Haemophilia. 2018; 24(4):641-647.","DOI":"10.1111\/hae.13461"},{"key":"74186","doi-asserted-by":"crossref","unstructured":"Andersson NG, Chalmers EA, Kenet G, Ljung R, M\u00e4kipernaa A, Chambost H. Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds. Haematologica. 2019; 104(10):2100-2106.","DOI":"10.3324\/haematol.2018.209619"},{"key":"74187","doi-asserted-by":"crossref","unstructured":"Kulkarni R, Presley RJ, Lusher JM. Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System. Haemophilia. 2017; 23(2):207-214.","DOI":"10.1111\/hae.13081"},{"key":"74188","doi-asserted-by":"crossref","unstructured":"Andersson NG, Auerswald G, Barnes C. Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment. Br J Haematol. 2017; 179(2):298-307.","DOI":"10.1111\/bjh.14844"},{"key":"74189","doi-asserted-by":"crossref","unstructured":"Witmer C, Presley R, Kulkarni R, Soucie JM, Manno CS, Raffini L. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol. 2011; 152(2):211-216.","DOI":"10.1111\/j.1365-2141.2010.08469.x"},{"key":"74190","doi-asserted-by":"crossref","unstructured":"Ljung R, de Kovel M, van den Berg HM, PedNet study g. Primary prophylaxis in children with severe haemophilia A and B-Implementation over the last 20 years as illustrated in real-world data in the PedNet cohorts. Haemophilia. 2023; 29(2):498-504.","DOI":"10.1111\/hae.14729"},{"key":"74191","doi-asserted-by":"crossref","unstructured":"Lindvall K, Colstrup L, Wollter IM. Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia. Haemophilia. 2006; 12(1):47-51.","DOI":"10.1111\/j.1365-2516.2006.01192.x"},{"key":"74192","doi-asserted-by":"crossref","unstructured":"Gouw SC, van der Bom JG, Ljung R. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013; 368(3):231-239.","DOI":"10.1056\/NEJMoa1208024"},{"key":"74193","doi-asserted-by":"crossref","unstructured":"Khair K, Ranta S, Thomas A, Lindvall K, PedNet study g. The impact of clinical practice on the outcome of central venous access devices in children with haemophilia. Haemophilia. 2017; 23(4):e276-e281.","DOI":"10.1111\/hae.13241"},{"key":"74194","doi-asserted-by":"crossref","unstructured":"Young G. Management of children with hemophilia A: how emicizumab has changed the landscape. J Thromb Haemost. 2021; 19(7):1629-1637.","DOI":"10.1111\/jth.15342"},{"key":"74195","doi-asserted-by":"crossref","unstructured":"Pipe SM, Collins PW, Dhalluin C. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial. Blood. 2024; 143(14):1355-1364.","DOI":"10.1182\/blood.2023021832"},{"key":"74196","doi-asserted-by":"crossref","unstructured":"Fischer K, Ljung R, Platokouki H. Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry. Haemophilia. 2014; 20(4):e280-286.","DOI":"10.1111\/hae.12448"},{"key":"74197","doi-asserted-by":"crossref","unstructured":"Morfini M, Agnelli Giacchiello J, Baldacci E. Managing relevant clinical conditions of hemophilia A\/B patients. Hematol Rep. 2023; 15(2):384-397.","DOI":"10.3390\/hematolrep15020039"},{"key":"74198","doi-asserted-by":"crossref","unstructured":"Melchiorre D, Linari S, Manetti M. Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A. Haematologica. 2016; 101(2):219-225.","DOI":"10.3324\/haematol.2015.133462"},{"key":"74199","doi-asserted-by":"crossref","unstructured":"Srivastava A, Rangarajan S, Kavakli K. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2023; 10(5):e322-e332.","DOI":"10.1016\/S2352-3026(23)00037-6"},{"key":"74200","doi-asserted-by":"crossref","unstructured":"Pasi KJ, Rangarajan S, Georgiev P. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017; 377(9):819-828.","DOI":"10.1056\/NEJMoa1616569"},{"key":"74201","doi-asserted-by":"crossref","unstructured":"Chowdary P, Lethagen S, Friedrich U. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015; 13(5):743-754.","DOI":"10.1111\/jth.12864"},{"key":"74202","doi-asserted-by":"crossref","unstructured":"Shapiro AD, Angchaisuksiri P, Astermark J. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors. Blood Adv. 2022; 6(11):3422-3432.","DOI":"10.1182\/bloodadvances.2021006403"},{"key":"74203","doi-asserted-by":"crossref","unstructured":"von Drygalski A, Chowdary P, Kulkarni R. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med. 2023; 388(4):310-318.","DOI":"10.1056\/NEJMoa2209226"},{"key":"74204","doi-asserted-by":"crossref","unstructured":"Konkle BA, Shapiro AD, Quon DV. BIVV001 Fusion protein as factor VIII replacement therapy for hemophilia A. N Engl J Med. 2020; 383(11):1018-1027.","DOI":"10.1056\/NEJMoa2002699"},{"key":"74205","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020; 26:1-158.","DOI":"10.1111\/hae.14046"},{"key":"74206","doi-asserted-by":"crossref","unstructured":"Andersson NG, Kenet G. Intracranial Hemorrhages in Neonates: Incidence, Risk Factors, and Treatment. Semin Thromb Hemost. 2023; 49(4):409-415.","DOI":"10.1055\/s-0042-1756195"},{"key":"74207","doi-asserted-by":"crossref","unstructured":"Boardman FK, Hale R, Young PJ. Newborn screening for haemophilia: the views of families and adults living with haemophilia in the UK. Haemophilia. 2019; 25(2):276-282.","DOI":"10.1111\/hae.13706"},{"key":"74208","doi-asserted-by":"crossref","unstructured":"Moorehead PC. Considering the benefits of newborn screening for haemophilia. Haemophilia. 2019; 25(4):e298-e299.","DOI":"10.1111\/hae.13776"},{"key":"74209","doi-asserted-by":"crossref","unstructured":"van Galen KPM, d\u2019Oiron R, James P. A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. J Thromb Haemost. 2021; 19(8):1883-1887.","DOI":"10.1111\/jth.15397"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11847\/77858","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11847\/78240","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11847\/77858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:44Z","timestamp":1794046064000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285874","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,28]]}}}